Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
The identification of disease clusters opens the door to a better stratification and classification of patients, beyond the traditional limited and diffuse cutaneous forms.
Recent randomized controlled trials have yielded encouraging results with new drugs targeting inflammatory/immunological and fibrotic pathways.
Further studies on the combination therapy of an antifibrotic with an immunosuppressant are needed to explore this very promising strategy in SSc.
One of the main unmet needs remains the early identification of patients at high mortality risk, for whom aggressiveness of therapies ought to be determined.
Recent data suggest that lung and cardiac transplantation may be taken into account in some carefully selected patients.
Systemic sclerosis (SSc) is a connective tissue disease characterized by diffuse microangiopathy and immune dysregulation which ultimately result in widespread fibrosis of skin and internal organs. Although the 2013 EULAR/ACR criteria have allowed to improve the sensitivity for SSc diagnosis, it has recently come to light that the traditional subclassification into limited and diffuse cutaneous forms does not appear to fully capture the different phenotypes of the scleroderma spectrum. In this regard, a recent large cluster analysis-based study and other ongoing projects are trying to achieve a better stratification of SSc patients, as the disease course remains largely unpredictable to date. Recent preclinical studies and randomized controlled trials have yielded encouraging results with new drugs targeting inflammatory/immunological and fibrotic pathways. One of the main unmet needs in SSc remains the early identification of patients at high mortality risk, for whom aggressiveness of therapies ought to be determined and weighed against disease prognosis. Furthermore, lung and cardiac transplantation may also be taken into account in some carefully selected patients. Though the prognosis of SSc remains poor, an optimized stratification of patients along with the recent and ongoing advances in therapies could greatly impact the natural course of the disease in the near future. Moreover, it is envisioned that there will be an increasing need in the future to further develop combination therapies to better fight against this complex disease. In this review we discussed new insights into organ involvements and therapeutic options.Le texte complet de cet article est disponible en PDF.
Keywords : Systemic sclerosis, Organ involvement, Vasodilators, Antifibrotics, Immunosuppressants